To understand the status of GSK3β pathway during apoptosis following treatment with TRAIL-TZD combination, prostate cancer cells (LNCaP and DU145) were treated with TRAIL-TZD combination for different lengths of time and changes in GSK3β levels were compared. This evidence concerns the gene GSK3B and prostate cancer.